Brigatinib: A Review in ALK-Inhibitor Naive Advanced ALK-Positive NSCLC

被引：10
|
作者：
Hoy, Sheridan M. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2021年 / 81卷 / 02期
关键词：
D O I：
10.1007/s40265-020-01449-y
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Brigatinib (Alunbrig(R)) is an oral, potent and selective anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor approved for treating adults with advanced ALK-positive non-small-cell lung cancer (NSCLC) not previously treated with an ALK inhibitor. In a multinational, phase III study (ALTA-1L) in this patient population, brigatinib significantly improved median blinded independent review committee-assessed progression-free survival (PFS), the confirmed objective response (OR) rate and the confirmed intracranial OR rate compared with crizotinib. Its tolerability profile in this study was manageable and no new safety concerns were identified. Although final analysis data are awaited with interest, brigatinib therapy extends the first-line treatment options available for standard of care in this patient population, including patients with CNS metastases.
引用
收藏
页码：267 / 275
页数：9
相关论文
共 50 条
  • [41] Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
    Harrer, Dennis Christoph
    Menhart, Karin
    Mayer, Stephanie
    Herr, Wolfgang
    Reichle, Albrecht
    Vogelhuber, Martin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [42] Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
    Chotai, S.
    Schmid, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1089 - S1089
  • [43] Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
    Waterhouse, David M.
    Espirito, Janet L.
    Chioda, Marc D.
    Baidoo, Bismark
    Mardekian, Jack
    Robert, Nicholas J.
    Masters, Elizabeth T.
    DRUGS-REAL WORLD OUTCOMES, 2020, 7 (04) : 261 - 269
  • [44] Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial
    Hida, T.
    Katayama, R.
    Nishio, M.
    Yoshida, T.
    Kumagai, T.
    Toyozawa, R.
    Shimokawaji, T.
    Goto, K.
    Nakagawa, K.
    Seto, T.
    Yamamoto, N.
    Asato, T.
    Hiraoka, K.
    Zhang, P.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S572 - S572
  • [45] Brigatinib Effective in ALK plus NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2017, 7 (01) : 4 - 5
  • [46] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
    Camidge, R.
    Kim, H. R.
    Ahn, M.
    Yang, J. C.
    Han, J.
    Lee, J.
    Hochmair, M.
    Li, J. Y.
    Chang, G.
    Lee, K.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
  • [47] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
    Califano, R.
    Camidge, D.
    Kim, H. -R.
    Ahn, M. -J.
    Yang, J.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Griesinger, F.
    Felip, E.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    LUNG CANCER, 2020, 139 : S59 - S60
  • [48] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [49] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
  • [50] Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC
    Zhang, Chao
    Yan, Li-Xu
    Jiang, Ben-Yuan
    Wu, Yi-Long
    Zhong, Wen-Zhao
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) : E95 - E99
12345